Highly sensitive determination of imidapril, a new angiotensin I-converting enzyme inhibitor, and its active metabolite in human plasma and urine using high-performance liquid chromatography with fluorescent labelling reagent.
A method for the simultaneous determination of imidapril and its active metabolite in human plasma and urine has been developed using high-performance liquid chromatography with a fluorescent labelling reagent, 9-anthryldiazomethane. Imidapril and its active metabolite were extracted from human plasma and urine using a solid-phase extraction cartridge (Bond Elut C18). Two compounds in the eluate were derivatized with 9-anthryldiazomethane and purified with a solid-phase extraction cartridge (Bond Elut SI). The derivatives were analysed using high-performance liquid chromatography with fluorometry. The detection limits of imidapril and its active metabolite were 0.2 ng/ml in plasma and 10 ng/ml in urine. This method could be applied to the pharmacokinetic study of imidapril.
Tagawa
K
K
Pharmaceutics Research Laboratory, Tanabe Seiyaku Co., Ltd., Osaka, Japan.
Hayashi
K
K
Mizobe
M
M
Noda
K
K
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000032:analysis* / Q000097:blood / Q000652:urine; D000873:Anthracenes; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D005456:Fluorescent Dyes; D006801:Humans; D007093:Imidazoles / Q000032:analysis* / Q000097:blood / Q000652:urine; D048289:Imidazolidines; D008297:Male; D015394:Molecular Structure; D015203:Reproducibility of Results; D013050:Spectrometry, Fluorescence
D000806:Angiotensin-Converting Enzyme Inhibitors; D000873:Anthracenes; D005456:Fluorescent Dyes; D007093:Imidazoles; D048289:Imidazolidines; C027347:9-diazomethylanthracene; C065166:imidapril